Loading stock data…
ACRS
$4.75+0.22 (+4.86%)
Pre-Market$4.78+0.03 (+0.63%)· Last close May 5
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aclaris Therapeutics, Inc. in the Healthcare sector is trading at $4.75. The stock is currently near its 52-week high of $4.89, remaining 69.6% above its 200-day moving average. Technical signals show neutral RSI of 69 and bullish MACD crossover, explaining why ACRS maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 69) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.75
Potential Upside
5%
Whystock Fair Value$4.99
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$550.95M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-62.98%
Volume
Today's trading volume
977,228
Recent News
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -40.54% and -2.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Aclaris...
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus
Aclaris Therapeutics (NASDAQ:ACRS) provided a clinical program update on Tuesday, highlighting full top-line results from its phase I-A single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ATI-052 and outlining plans to advance oral candidate ATI-2138 into a phase IIb program in li
Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming
Aclaris Therapeutics (NASDAQ:ACRS) used an H.C. Wainwright inflammatory skin diseases conference fireside chat to outline development plans and differentiation points for its lead biologic candidate, ATI-052, and to provide updates on its small-molecule pipeline. ATI-052: bispecific approach and ea
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.